MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction with Pulmatrix
Valencia, Calif. October XX, 2023’ - MannKind Corporation, a company at the forefront of developing innovative inhalation technologies, today announced a strategic transaction with Pulmatrix, Inc. to expand its Research & Development (R&D) capabilities and its cutting-edge portfolio of dry powder inhalation technology. This move will significantly bolster MannKind’s presence in the highly dynamic Boston area, a region known for its concentration of biotech and pharmaceutical R&D activities.
Strategic Acquisition to Solidify Position in Inhalation Technology
The collaboration with Pulmatrix represents a significant step forward for MannKind as it secures key assets and intellectual property that align with its mission to deliver novel therapies via its proprietary Technosphere® platform. By integrating Pulmatrix’s advanced dry powder formulations and inhalation delivery systems, MannKind not only diversifies its product pipeline but also strengthens its capability to accelerate the development of next-generation therapies targeting pulmonary and systemic diseases.
According to Michael Castagna, PharmD, CEO of MannKind Corporation, This acquisition marks a pivotal moment in our expansion strategy. Establishing an R&D foothold in the Boston area will give us direct access to a unique ecosystem of scientific innovation and collaboration opportunities. Combined with Pulmatrix’s proven inhalation technologies, we are well-positioned to advance our development programs and ultimately deliver more impactful therapies to patients.
Robust Financial Growth
The strategic expansion coincides with a period of robust financial growth for MannKind. In the most recent fiscal year, the company recorded a year-on-year revenue increase of an impressive 157.28%, demonstrating the effectiveness of its strategic initiatives and its growing market presence. Moreover, MannKind’s sequential revenue growth reached 19.65%, underscoring the company’s consistent performance and profitability.
This revenue uptick highlights MannKind’s successful commercialization efforts and expanding product footprint in the competitive pharmaceutical market. The partnership with Pulmatrix is expected to sustain this upward trajectory by adding valuable assets that are poised for rapid development and market penetration.
Expanding the Research & Development Ecosystem
The Boston area is recognized globally as a hub for biotechnology and pharmaceutical research, offering unparalleled resources, talent, and collaborative opportunities. By establishing a strong R&D foothold in this region, MannKind aims to leverage these advantages to enhance its research capabilities and expedite the development of innovative inhalation therapies.
Pulmatrix’s cutting-edge dry powder technology is designed to deliver a wide range of therapeutics via the respiratory route, offering potential benefits such as improved drug delivery efficiency, patient compliance, and therapeutic efficacy. MannKind plans to integrate this technology with its own proprietary platforms, pushing the boundaries of what’s possible in inhalation medicine.
We are excited by the potential of MannKind’s expanded R&D presence in Boston,” said Dr. Robert Clarke, CEO of Pulmatrix. “Our dry powder inhalation platform holds great promise, and combining it with MannKind’s expertise and resources will unlock new therapeutic possibilities. Together, we are poised to make significant advancements in patient care.
Looking Forward
As MannKind continues to execute its strategic plans, the company remains committed to innovation and patient-centric solutions. The acquisition of Pulmatrix’s assets is not merely a financial transaction but a strategic alignment that will drive scientific discovery and medical advancements.
The establishment of a Boston-area R&D center enables MannKind to deepen its engagement with the scientific community, foster partnerships, and pioneer the future of inhalation therapies. With a solid financial foundation and an enhanced product portfolio, MannKind is well-positioned to lead the industry in delivering impactful solutions for patients worldwide.
Comments